γ-globin gene therapy (CSL Behring)

N/A

Report date: 2023/10/26 16:03:59

Base Information

Drug Nameγ-globin gene therapy (CSL Behring)
Drug Alias Nameγ-珠蛋白基因疗法-CSL BehringCSL-200
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionGene transferenceHemoglobin beta chain stimulants
TargetsHemoglobin beta chainHematopoietic progenitor cell antigen CD34
Therapy Area/IndicationsAnemia, Sickle Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCsl Behring Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCsl Behring
Active IndicationsN/A
Inactive IndicationsAnemia, Sickle Cell

Other Information

ATC CodeN/A
Related LinksN/A